JCR Pharmaceuticals Co.,Ltd
4552・Prime Market・Pharmaceuticals
Governance
The company operates as a company with a Board of Corporate Auditors, with the Board of Directors comprising 12 directors, including 7 outside directors (outside director ratio of 58.3%). It has established a Nomination and Compensation Advisory Committee, building a framework in which independent outside directors take a central role in providing recommendations regarding the nomination and compensation of directors and executive officers.
Risk Management
The Risk Management Promotion Meeting is held on a regular basis under the Chief Risk Management Officer appointed by the President, consolidating and managing risk-related activities across all departments. The company has established Basic Regulations for Risk Management, formulated a BCP, and set up a quality and safety assurance framework through the Three Officers' Meeting for Manufacturing and Marketing Business based on the Pharmaceuticals and Medical Devices Act.
Shareholder Returns
The basic policy is to pay continuous and stable dividends, with the annual dividend for FY2026 (ending March 2026) set at ¥20 per share (interim ¥10, year-end ¥10), total dividends of ¥2,444 million, and a payout ratio of 111.9%. The same amount of ¥20 is planned for FY2027 (ending March 2027) as well. No share buybacks are planned.
Dividend Policy
The basic policy is to pay continuous and stable dividends while taking into account business performance and cash flow conditions, while securing internal reserves to strengthen the management foundation and fund new drug development, which serves as a source of future profits. Interim and year-end dividends are paid twice a year. The annual dividend for FY2026 (ending March 2026) is ¥20 per share (interim ¥10, year-end ¥10), with total dividends of ¥2,444 million, a payout ratio of 111.9%, and a dividend-to-net-assets ratio of 5.2%. For FY2027 (ending March 2027), the same ¥20 per share (interim ¥10, year-end ¥10) is planned.
ESG
With rare diseases, environment, society, and governance as key focus areas, the company is advancing GHG emissions disclosure (Scope 1+2+3 total of 74,606 tCO₂) and its response to TCFD recommendations. In terms of human capital, the company discloses achievements including a female employee ratio of 41.7%, a male childcare leave uptake rate of 93.5%, and training costs of ¥102,000 per employee, while also working on next-generation leader development through the JCR Academy.
Last updated: June 23, 2026